The AMNOG Knowledge Graph

22,359 endpoints across 973 assessments · IQWiG §35a SGB V, 2011–present

Ask Browse

22,359

Endpoint assessments

11,817

Methodological disputes

2,042

Included studies

2,577

Rejected evidence

Benefit rating distribution

1,413 rated subgroups

Major
45 3%
Considerable
111 8%
Minor
86 6%
Non-quantifiable
89 6%
Not proven
1,025 73%
Less than comparator
57 4%

By therapeutic area

 

Cancer
576
Digestion, metabolism and hormones
184
Immune system and infections
117
Head and nerves
103
Heart and circulation
65
Haematology
64
Airways and respiratory system
62
Skin and hair
61
Muscles, bones and joints
60
Oncology
38
Children's and adolescents' health
19
Kidneys and urinary system
17

Assessments by year

1
2
5
6
8
9
32
37
45
43
55
82
66
78
109
99
163
138
136
139
164
86
05060708091011121314151617181920212223242526

Recently published

A25-160Nipocalimab2026-06-18
A26-51NipocalimabAdd.2026-06-18
MP-202406Tovorafenib2026-06-18
MP-202525Cosibelimab2026-06-18
A26-25Mepolizumab2026-06-15